Phenobarbital increases monkeyin vivonicotine disposition and induces liver and brain CYP2B6 protein
Open Access
- 1 July 2006
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 148 (6) , 786-794
Abstract
CYP2B6 is a drug‐metabolizing enzyme expressed in the liver and brain that can metabolize bupropion (Zyban®, a smoking cessation drug), activate tobacco‐smoke nitrosamines, and inactivate nicotine. Hepatic CYP2B6 is induced by phenobarbital and induction may affectin vivonicotine disposition, while brain CYP2B6 induction may affect local levels of centrally acting substrates. We investigated the effect of chronic phenobarbital treatment on induction ofin vivonicotine disposition and CYP2B6 expression in the liver and brain of African Green (Vervet) monkeys. Monkeys were split into two groups (n=6 each) and given oral saccharin daily for 22 days; one group was supplemented with 20 mg kg−1phenobarbital. Monkeys were given a 0.1 mg kg−1nicotine dose subcutaneously before and after treatment. Phenobarbital treatment resulted in a significant, 56%, decrease (P=0.04) in the maximum nicotine plasma concentration and a 46% decrease (P=0.003) in the area under the concentration–time curve. Phenobarbital also increased hepatic CYP2B6 protein expression. In monkey brain, significant induction (Pin vivonicotine disposition, and induced hepatic and brain CYP2B6 protein levels and cellular expression. This induction may alter the metabolism of CYP2B6 substrates including peripherally acting drugs such as cyclophosphamide and centrally acting drugs such as bupropion, ecstasy and phencyclidine. British Journal of Pharmacology(2006)148, 786–794. doi:10.1038/sj.bjp.0706787Keywords
This publication has 49 references indexed in Scilit:
- CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatmentNeuropharmacology, 2006
- NICOTINE AND 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-BUTANONE METABOLISM BY CYTOCHROME P450 2B6Drug Metabolism and Disposition, 2005
- CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONSDrug Metabolism and Disposition, 2005
- Expression of Constitutive Androstane Receptor Splice Variants in Human Tissues and Their Functional ConsequencesThe Journal of Pharmacology and Experimental Therapeutics, 2004
- AN ASSESSMENT OF UDP-GLUCURONOSYLTRANSFERASE INDUCTION USING PRIMARY HUMAN HEPATOCYTESDrug Metabolism and Disposition, 2004
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brainNeuropharmacology, 2003
- An in Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 AllelesBiochemical and Biophysical Research Communications, 2002
- Nicotine's role in smoking: An analysis of nicotine regulation.Psychological Bulletin, 1983
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976